前交叉韧带重建术后能否消除阿片类药物?一项前瞻性随机对照试验
该随机对照试验比较多模式非阿片类镇痛方案与传统阿片类药物在前交叉韧带重建术后的镇痛效果。共分析62例患者,非阿片组34例、阿片组28例。结果显示非阿片组VAS疼痛评分显著更低(P < .05),调整混杂因素后两组疼痛控制无显著差异,所有非阿片组患者对疼痛管理满意。
要点
- 多模式非阿片类方案在ACLR术后提供至少等效的疼痛控制。
- 非阿片组VAS评分显著低于阿片组(P < .05)。
- 两组不良反应最常见为嗜睡和便秘,无组间差异。
核心结论
- 多模式非阿片类镇痛方案在ACLR术后患者中提供了至少与传统阿片类镇痛药等效的疼痛控制。
- 两组不良反应轻微且无差异,所有非阿片组患者报告疼痛管理满意。
研究设计与样本
- 前瞻性随机对照试验,证据等级1,遵循CONSORT 2010声明。
- 90例初次ACLR患者评估参与,最终62例分析(阿片组28例,非阿片组34例)。
- 非阿片组方案包括对乙酰氨基酚、酮咯酸、地西泮、加巴喷丁和美洛昔康;阿片组方案为氢可酮-对乙酰氨基酚。
- 主要结局为术后10天视觉模拟量表(VAS)疼痛评分,观察者设盲,患者未设盲。
主要发现
- 非阿片组VAS评分显著低于阿片组(P < .05)。
- 术前PROMIS疼痛干扰简表评分:阿片组58.6 ± 7.9,非阿片组57.5 ± 7.4,P = .385。
- 术后1周PROMIS疼痛干扰简表评分:阿片组66.3 ± 8.2,非阿片组61.4 ± 8.8,P = .147。
- 调整年龄、性别、体重指数、移植物类型后,两组疼痛控制无显著差异。
- 两组最常见不良反应为嗜睡和便秘,无组间差异。
关键数值与推荐
- 主要结局VAS评分非阿片组显著更低(P < .05)。
- PROMIS疼痛干扰简表术前评分P = .385,术后1周P = .147。
临床怎么用
- ACLR术后可考虑采用多模式非阿片类镇痛方案替代传统阿片类药物。
- 该方案在提供等效镇痛的同时可能减少阿片类药物消耗。
局限性
- 患者未对干预设盲。
- 最终分析样本量62例,少于最初评估的90例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multimodal pain protocols have been effective for postsurgical pain control; however, no published protocol has been effective in eliminating opioid consumption. PURPOSE: To compare a multimodal nonopioid pain protocol versus traditional opioid medication for postoperative pain control in patients undergoing anterior cruciate ligament reconstruction (ACLR). STUDY DESIGN: Randomized controlled trial; Level of evidence, 1. METHODS: A total of 90 patients undergoing primary ACLR were assessed for participation. We performed a prospective, randomized controlled trial in accordance with the CONSORT (Consolidated Standards of Reporting Trials) 2010 statement. The study arms were a multimodal nonopioid analgesic protocol (acetaminophen, ketorolac, diazepam, gabapentin, and meloxicam) and a standard opioid regimen (hydrocodone-acetaminophen), and the primary outcome was postoperative visual analog scale (VAS) pain scores for 10 days. Secondary outcomes included patient-reported outcomes, complications, and satisfaction. The observers were blinded, and the patients were not blinded to the intervention. RESULTS: A total of 9 patients did not meet inclusion criteria, and 19 patients declined participation. Thus, 62 patients were analyzed, with 28 patients randomized to the opioid group and 34 to the multimodal nonopioid group. Patients receiving the multimodal nonopioid pain regimen demonstrated significantly lower VAS scores compared with patients who received opioid pain medication (P < .05). Patients were administered the Patient-Reported Outcomes Measurement and Information System Pain Interference Short Form, and no significant difference was found in patients' preoperative scores (opioid group, 58.6 ± 7.9; multimodal nonopioid group, 57.5 ± 7.4; P = .385) and 1-week postoperative scores (opioid group, 66.3 ± 8.2; multimodal nonopioid group, 61.4 ± 8.8; P = .147). When we adjusted for possible confounders (age, sex, body mass index, graft type), no significant differences in pain control were found between the 2 groups. The most common adverse effects for both groups were drowsiness and constipation, with no difference between the groups. All patients in the multimodal nonopioid group reported satisfactory pain management. CONCLUSIONS: A multimodal nonopioid pain protocol provided at least equivalent pain control compared with traditional opioid analgesics in patients undergoing ACLR. Minimal side effects, which did not differ between groups, were noted, and all patients reported satisfaction with their pain management.
引用
- Moutzouros V, Jildeh TR, Tramer JS, et al. Can We Eliminate Opioids After Anterior Cruciate Ligament Reconstruction? A Prospective, Randomized Controlled Trial. Am J Sports Med. 2021. PMID: 34668795. doi:10.1177/03635465211045394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。